AEON is the former parent company of EOLS, which sells Jeuveau botulinum toxin for aesthetic indications. AEON’s ABP-450 is the same drug as Jeuveau, but AEON is seeking approval in therapeutic indications only, starting with cervical dystonia.
Daewoong of Korea is the toxin supplier for both EOLS and AEON.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.